<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871607</url>
  </required_header>
  <id_info>
    <org_study_id>20420</org_study_id>
    <secondary_id>NCI-2021-03073</secondary_id>
    <secondary_id>20420</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <nct_id>NCT04871607</nct_id>
  </id_info>
  <brief_title>Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody&#xD;
      combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that&#xD;
      does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled&#xD;
      anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is&#xD;
      attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy&#xD;
      drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,&#xD;
      or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell&#xD;
      transplant helps kill cancer cells in the body and helps make room in the patient's bone&#xD;
      marrow for new blood-forming cells (stem cells) to grow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the anti-lymphoma activity of the aTac-carmustine (BCNU), etoposide, cytarabine&#xD;
      (cytosine arabinoside), and melphalan (BEAM) regimen as conditioning for Autologous&#xD;
      hematopoietic cell transplantation (AHCT); assessed by 2-year progression-free survival&#xD;
      (PFS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the overall survival (OS) probability and cumulative incidence of&#xD;
      relapse/progression, and non-relapse mortality (NRM) at 100-days, 1-year and 2-years.&#xD;
&#xD;
      II. Summarize toxicities by type, frequency, severity, attribution, time course and duration.&#xD;
&#xD;
      III. Evaluate short and long-term complications, including: delayed engraftment (neutrophil&#xD;
      and platelet), infection, and myelodysplasia (MDS).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate potential changes in Hodgkin lymphoma biological markers of patients treated with&#xD;
      90Y basiliximab BEAM via analyses of serial blood samples.&#xD;
&#xD;
      II. Assess the potential association between pre-AHCT CD25 expression levels and post-AHCT&#xD;
      outcomes.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 'cold' basiliximab intravenously (IV) followed by yttrium Y 90 basiliximab&#xD;
      IV on day -14. Patients also receive carmustine IV on over 4 hours day -6, etoposide IV over&#xD;
      1 hours once daily (QD) and cytarabine IV over 2 hours twice daily (BID) on days -5 to -2,&#xD;
      and melphalan IV over 1 hours on day -1. Patients then receive hematopoietic progenitor cell&#xD;
      apheresis (HPC-A) product via infusion on day 0. Beginning day 5, patients receive&#xD;
      granulocyte colony-stimulating factor (G-CSF) (or biosimilar) subcutaneously (SC) or IV until&#xD;
      absolute neutrophil count (ANC) &gt; 500 for 3 consecutive days or according to the treating&#xD;
      physician's best clinical judgement.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, up to 2 years for&#xD;
      response, and up to 5 years for survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the start of treatment up to 5 years post transplant</time_frame>
    <description>Disease relapse or progression, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start of treatment up to 5 years post transplant</time_frame>
    <description>Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse or progression</measure>
    <time_frame>From the start of treatment up to 5 years post transplant</time_frame>
    <description>Relapse or progression of Hodgkin lymphoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>From the start of treatment up to 5 years post transplant</time_frame>
    <description>Death from causes other than relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicities and adverse events</measure>
    <time_frame>Day -14 to day 100 post-transplant</time_frame>
    <description>Toxicity information recorded will include the type, severity, and the probable association with the study regimen. Tables will be constructed to summarize the observed incidence by severity and type of toxicity. Toxicities will be recorded using both the Bearman criteria and the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematopoietic recovery</measure>
    <time_frame>Up to day 100 post transplant</time_frame>
    <description>Time to neutrophil recovery will be the first of three consecutive days of ≥ 500 neutrophils/µL following the expected nadir. Time to platelet engraftment will be the first day of the first of three consecutive daily laboratory values when the platelet count is ≥20,000/µL, without a platelet transfusion in the previous seven days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>Day -14 to day 100 post-transplant</time_frame>
    <description>Microbiologically documented infections will be reported by site of disease, date of onset, severity and resolution, if any.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of secondary myelodysplastic syndrome</measure>
    <time_frame>From the start of treatment up to 5 years post transplant</time_frame>
    <description>Secondary MDS or AML post therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 'cold' basiliximab IV followed by yttrium Y 90 basiliximab 0.6 mCi/kg IV on day -14.&#xD;
Patients also receive carmustine 300 mg/m2 IV on over 4 hours day -6, etoposide 200 mg/m2 IV over 1 hours QD and cytarabine 200 mg/m2 IV over 2 hours BID on days -5 to -2, and melphalan 140 mg/m2 IV over 1 hours on day -1.&#xD;
Patients then receive HPC-A product via infusion on day 0. Beginning day 5, patients receive G-CSF (or biosimilar) SC or IV until ANC &gt; 500 for 3 consecutive days or according to the treating physician's best clinical judgement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Anti-CD25 antibody given IV</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <other_name>SDZ-CHI-621</other_name>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Cytotoxic chemotherapy; alkylating agent given IV</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>N,N''-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytotoxic chemotherapy; antimetabolite given IV</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Cytotoxic chemotherapy; topoisomerase II inhibitor given IV</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplantation</intervention_name>
    <description>Patients will receive their own stem cells, collected prior to conditioning given via IV infusion</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium - 90 Basiliximab</intervention_name>
    <description>Radio-conjugate of anti-CD25 antibody given IV</description>
    <arm_group_label>Treatment (yttrium Y 90 basiliximab, chemotherapy, HPC-A)</arm_group_label>
    <other_name>90Y Basiliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented informed consent of the participant and/or legally authorized&#xD;
             representative&#xD;
&#xD;
               -  Assent, when appropriate, will be obtained per institutional guidelines&#xD;
&#xD;
          -  Age: &gt;= 18 years&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70%&#xD;
&#xD;
          -  Life expectancy &gt;= 6 months&#xD;
&#xD;
          -  Histologically confirmed Hodgkin lymphoma (HL)&#xD;
&#xD;
          -  Relapsed/refractory disease&#xD;
&#xD;
               -  PIF (primary induction failure): Did not enter complete remission with first line&#xD;
                  of therapy. Note: a patient with PIF who responds to salvage therapy with a&#xD;
                  partial response (PR) or complete response (CR) is also eligible (and would be&#xD;
                  considered PIF-sensitive)&#xD;
&#xD;
               -  Early 1st relapse: Initial CR of &gt; 3 months and &lt; 12 months after 1st line&#xD;
                  chemotherapy&#xD;
&#xD;
               -  1st relapsed HL in a patient who is not in CR after 2 different salvage therapy&#xD;
                  regimens to attain CR&#xD;
&#xD;
               -  In 2nd or subsequent RL whether in CR or not after salvage therapy&#xD;
&#xD;
          -  High risk relapsed or refractory HL disease defined as having any one of the&#xD;
             following:&#xD;
&#xD;
               -  B symptoms at relapse&#xD;
&#xD;
               -  Extranodal disease at relapse&#xD;
&#xD;
               -  Primary refractory disease&#xD;
&#xD;
               -  Relapse &lt; 1 year after completion of frontline therapy&#xD;
&#xD;
               -  Not in CR at the time of transplant&#xD;
&#xD;
               -  Relapse after receiving PD1 blockade or brentuximab vedotin as initial therapy&#xD;
&#xD;
          -  Patients will be enrolled after collection of at least 2.0 x 10^6 CD34 cells/kg of&#xD;
             autologous hematopoietic progenitor cells (HPC-A) by apheresis&#xD;
&#xD;
          -  Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to =&lt;&#xD;
             grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL (performed prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Creatinine clearance of &gt;= 60 mL/min per 24 hour urine test =&lt; 1.5 mg/dL (performed&#xD;
             prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease)&#xD;
             (performed prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) =&lt; 1.5&#xD;
             x ULN (except in cases where abnormal liver function tests (LFTs) are due to&#xD;
             involvement with HL) (performed prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =&lt; 1.5 x&#xD;
             ULN (except in cases where abnormal LFTs are due to involvement with HL) (performed&#xD;
             prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50% (performed prior to day 1 of protocol&#xD;
             therapy)&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) &gt; 65% of predicted measured, or DLCO&#xD;
             (diffusion capacity) &gt;= 50% of predicted measured (corrected for hemoglobin)&#xD;
             (performed prior to day 1 of protocol therapy)&#xD;
&#xD;
          -  Agreement by females and males of childbearing potential to use an effective method of&#xD;
             birth control or abstain from heterosexual activity for the course of the study&#xD;
             through at least six months after the last dose of protocol therapy&#xD;
&#xD;
               -  Childbearing potential defined as not being surgically sterilized (men and women)&#xD;
                  or have not been free from menses for &gt; 1 year (women only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned BV consolidation after AHCT&#xD;
&#xD;
          -  Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic&#xD;
             transplantation&#xD;
&#xD;
          -  Significant prior external beam dose-limiting radiation to a critical organ based on&#xD;
             review of the prior radiation treatment records by the radiation oncology principal&#xD;
             investigator (PI)&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents, or concurrent&#xD;
             biological, chemotherapy, or radiation therapy&#xD;
&#xD;
          -  Myelodysplasia or any active malignancy other than HL, or &lt; 5 years remission from any&#xD;
             other prior malignancy, except non-melanoma skin cancer, localized prostate cancer or&#xD;
             localized cervical cancer&#xD;
&#xD;
          -  Any cytogenetic abnormality in the bone marrow that is known to be associated with or&#xD;
             predictive of myelodysplasia is excluded. This includes, but is not limited to,&#xD;
             del(5), del(7), del(11)&#xD;
&#xD;
          -  Lymphocyte-predominant Hodgkin lymphoma&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to 90Y-basiliximab-DOTA&#xD;
&#xD;
          -  Presence of antibodies against basiliximab (only required for patients who have&#xD;
             received prior antibody therapy)&#xD;
&#xD;
          -  Persistent marrow involvement (&gt; 10%) with HL after salvage cytoreductive therapy and&#xD;
             before stem cell mobilization&#xD;
&#xD;
          -  Bone marrow (BM) harvest required to reach adequate cell dose for transplant&#xD;
&#xD;
          -  Active hepatitis B or C viral infection or hepatitis B surface antigen positive&#xD;
&#xD;
          -  Positive human immunodeficiency virus antibody, patients with undetectable human&#xD;
             immunodeficiency virus (HIV) viral load with CD4 &gt;= 300 and are on highly active&#xD;
             antiretroviral therapy (HAART) medication are allowed&#xD;
&#xD;
          -  Patients should not have any uncontrolled illness including ongoing or active&#xD;
             infection&#xD;
&#xD;
          -  Patients with psychosocial circumstances or illnesses that preclude protocol&#xD;
             participation (to be determined by P.I.)&#xD;
&#xD;
          -  Pregnant women are excluded from this study because 90Y-basiliximab/DOTA is an agent&#xD;
             with the potential for teratogenic or abortifacient effects. Because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother 90Y-basiliximab/DOTA, breastfeeding should be discontinued if&#xD;
             the mother is treated with 90Y-basiliximab/DOTA&#xD;
&#xD;
          -  Any other condition that would, in the investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns with clinical&#xD;
             study procedures&#xD;
&#xD;
          -  Any other condition that would, in the Investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns with clinical&#xD;
             study procedures&#xD;
&#xD;
          -  Prospective participants who, in the opinion of the investigator, may not be able to&#xD;
             comply with all study procedures (including compliance issues related to&#xD;
             feasibility/logistics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex F Herrera</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex F. Herrera</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>62405</phone_ext>
      <email>aherrera@coh.org</email>
    </contact>
    <investigator>
      <last_name>Alex F. Herrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

